Friday, January 15, 2021 Headlines | Marijuana Today Daily News

Marijuana Today Daily Headlines
Friday, January 15, 2021 | Curated by host Shea Gunther

// Marijuana Sales Broke $2 Billion for 2020 by November (Denver Westword)

// Virginia Governor Unveils Bill To Legalize Marijuana As Lawmakers Schedule First Hearing (Marijuana Moment)

// BREAKING NEWS: Cannabis for Medical Use Just Became Fully Legal in Mexico (Canna Law Blog)


These headlines are brought to you by MJToday Media, publishers of this podcast as well as our weekly show Marijuana Today and the most-excellent Green Rush Podcast. And check out our new show Weed Wonks!


shee
// MD cannabis staffers get same COVID vaccine status as health-care workers (Marijuana Business Daily)

// New Mexico Governor Says Marijuana Legalization Is A 2021 Priority (Marijuana Moment)

// Marijuana MSO Cresco inks $213M all-stock deal to expand into Florida (Marijuana Business Daily)

// Rhode Island’s Likely Next Governor Backs Private Legal Marijuana Model Over State-Run Market (Marijuana Moment)

// Michigan Prosecutor Won’t Pursue Most Marijuana Or Psychedelics Cases ‘Regardless Of The Amount’ (Marijuana Moment)

// GW Pharma expects fiscal 2020 sales to reach $526 million (Marijuana Business Daily)

// Texas Woman Connected to Oklahoma Marijuana Industry Arrested for Rioting in DC (Celeb Stoner)

Check out our other projects:Marijuana Today— Our flagship title, a weekly podcast examining the world of marijuana business and activism with some of the smartest people in the industry and movement. • Marijuana Media Connect— A service that connects industry insiders in the legal marijuana industry with journalists, bloggers, and writers in need of expert sources for their stories.

Love these headlines? Love our podcast? Support our work with a financial contribution and become a patron.

Photo: Barry Dale Gilfry/Flickr

Best UK CBD Products 2020

Finding the best CBD products isn’t always easy. You’ll want to make sure you’re buying them from a reputable company and that they’re made from the highest quality ingredients possible. You need to find a company that sells only the best products, has a good reputation, and can meet your expectations.  To give you a […]

The post Best UK CBD Products 2020 appeared first on Latest Cannabis News Today – Headlines, Videos & Stocks.

Tuesday, August 4, 2020 Headlines | Marijuana Today Daily News

Marijuana Today Daily Headlines
Tuesday, August 4, 2020 | Curated by host Shea Gunther

// Cannabis, Lies, and Foreign Cash: A Mother and Daughter’s Journey Through the Underground Mask Trade (Pro Publica)

// Tight capital markets – worsened by COVID-19 – derail Schwazze’s cannabis acquisitions (Marijuana Business Daily)

// Black residents made up 97% of marijuana arrests in New York state capital (Leafly (AP))


These headlines are brought to you by Green Worx Consults, a company specializing in project management, workflow mapping and design, and Lean & 6 Sigma process. If you could use help making your business better at business, get in touch with Green Worx Consults.


// Analyzing Congress’s Latest Vote To Protect Legal Marijuana States From Federal Enforcement (Marijuana Moment)

// FDA approves GW Pharmaceuticals’ cannabis drug for new indication (Marijuana Business Daily)

// Massachusetts Senator Gives Wicked Chill Marijuana Response To Blunt-Smoking Constituent (Marijuana Moment)

// Major Cannabis Companies Shun Oklahoma (Fresh Toast)

// The pandemic is eating away at the illicit marijuana market (Politico)

// Louisiana Law Allowing Medical Marijuana For Any Debilitating Condition To Take Effect (Marijuana Moment)

// Recreational marijuana sales reached almost $61 million in July, setting a record for the third month in a row (Chicago Tribune)


Check out our other projects:Marijuana Today— Our flagship title, a weekly podcast examining the world of marijuana business and activism with some of the smartest people in the industry and movement. • Marijuana Media Connect— A service that connects industry insiders in the legal marijuana industry with journalists, bloggers, and writers in need of expert sources for their stories.

Love these headlines? Love our podcast? Support our work with a financial contribution and become a patron.

Photo: michael_swan/Flickr

Tuesday, May 12, 2020 Headlines | Marijuana Today Daily News

Marijuana Today Daily Headlines
Tuesday, May 12, 2020 | Curated by host Shea Gunther

// Maine drops residency requirement for recreational marijuana businesses (Portland Press Herald)

// Maine’s adult-use marijuana program won’t start until more local approvals in place (Marijuana Business Daily)

// Maryland Governor Hogan Vetoes Bill Automatically Expunging Cannabis Convictions (Outlaw Report)


These headlines are brought to you by MJToday Media, publishers of this podcast as well as our weekly show Marijuana Today and the most-excellent Green Rush Podcast. And check out our new show Weed Wonks!


// Trulieve’s dominance in Florida increases again as many firms come to a standstill (Marijuana Business Daily)

// Epidiolex Growth Fuels GW Pharma Revenue Above Expectations to $120.6 Million (New Cannabis Ventures)

// Tilray Q1 Cannabis Revenue Grows 9% Sequentially to $30.8 Million (New Cannabis Ventures)

// Cronos Group Underwhelms Again with Just $8.4 Million Revenue and a $45.1 Million Operating Loss in Q1 (New Cannabis Ventures)

// Cannabis MSO Jushi cancels California acquisition, moves forward in Illinois (Marijuana Business Daily)

// Mass. cannabis executives ‘look forward to safely reopening’ after meeting with governor’s advisory board (Mass Live)

// Top Vermont Lawmaker Says Legal Marijuana Sales Bill Will Be Taken Up After Coronavirus Response (Marijuana Moment)


Check out our other projects:Marijuana Today— Our flagship title, a weekly podcast examining the world of marijuana business and activism with some of the smartest people in the industry and movement. • Marijuana Media Connect— A service that connects industry insiders in the legal marijuana industry with journalists, bloggers, and writers in need of expert sources for their stories.

Love these headlines? Love our podcast? Support our work with a financial contribution and become a patron.

Photo: Paul Noble Photography/Flickr

Friday, June 26, 2020 Headlines | Marijuana Today Daily News

Marijuana Today Daily Headlines
Friday, June 26, 2020 | Curated by host Shea Gunther

// New Jersey medical marijuana dispensaries can now deliver (Marijuana Business Daily)

// Idaho Medical Marijuana Initiative Could Get New Chance At Ballot After Federal Court Ruling (Marijuana Moment)

// Canopy Growth Changes Acreage Holdings Deal CEO Murphy Is Out (Green Market Report)


These headlines are brought to you by Green Worx Consults, a company specializing in project management, workflow mapping and design, and Lean & 6 Sigma process. If you could use help making your business better at business, get in touch with Green Worx Consults.


// Washington State Drug Decriminalization Activists Shift Focus From Ballot To Legislature (Marijuana Moment)

// Los Angeles City Council backs major changes to marijuana licensing, social equity (Marijuana Business Daily)

// Canada’s discount cannabis segment heats up with competing value brands (Marijuana Business Daily)

// Seattle repeals drug loitering law that led to racist harassment and arrests (Leafly)

// GW Pharmaceuticals Epidiolex Now Exempt From Controlled Drug Requirements (Green Market Report)

// Federal Commission Pushes Expansion Of Marijuana And Psychedelics Research For Military Veterans (Marijuana Moment)

// Virginia Black Lawmakers Push To Legalize Marijuana In Special Session This Summer (Marijuana Moment)


Check out our other projects:Marijuana Today— Our flagship title, a weekly podcast examining the world of marijuana business and activism with some of the smartest people in the industry and movement. • Marijuana Media Connect— A service that connects industry insiders in the legal marijuana industry with journalists, bloggers, and writers in need of expert sources for their stories.

Love these headlines? Love our podcast? Support our work with a financial contribution and become a patron.

Photo: Marketeering Group/Flickr

Friday, June 26, 2020 Headlines | Marijuana Today Daily News

Marijuana Today Daily Headlines
Friday, June 26, 2020 | Curated by host Shea Gunther

// New Jersey medical marijuana dispensaries can now deliver (Marijuana Business Daily)

// Idaho Medical Marijuana Initiative Could Get New Chance At Ballot After Federal Court Ruling (Marijuana Moment)

// Canopy Growth Changes Acreage Holdings Deal CEO Murphy Is Out (Green Market Report)


These headlines are brought to you by Green Worx Consults, a company specializing in project management, workflow mapping and design, and Lean & 6 Sigma process. If you could use help making your business better at business, get in touch with Green Worx Consults.


// Washington State Drug Decriminalization Activists Shift Focus From Ballot To Legislature (Marijuana Moment)

// Los Angeles City Council backs major changes to marijuana licensing, social equity (Marijuana Business Daily)

// Canada’s discount cannabis segment heats up with competing value brands (Marijuana Business Daily)

// Seattle repeals drug loitering law that led to racist harassment and arrests (Leafly)

// GW Pharmaceuticals Epidiolex Now Exempt From Controlled Drug Requirements (Green Market Report)

// Federal Commission Pushes Expansion Of Marijuana And Psychedelics Research For Military Veterans (Marijuana Moment)

// Virginia Black Lawmakers Push To Legalize Marijuana In Special Session This Summer (Marijuana Moment)


Check out our other projects:Marijuana Today— Our flagship title, a weekly podcast examining the world of marijuana business and activism with some of the smartest people in the industry and movement. • Marijuana Media Connect— A service that connects industry insiders in the legal marijuana industry with journalists, bloggers, and writers in need of expert sources for their stories.

Love these headlines? Love our podcast? Support our work with a financial contribution and become a patron.

Photo: Marketeering Group/Flickr

Tuesday, May 12, 2020 Headlines | Marijuana Today Daily News

Marijuana Today Daily Headlines
Tuesday, May 12, 2020 | Curated by host Shea Gunther

// Maine drops residency requirement for recreational marijuana businesses (Portland Press Herald)

// Maine’s adult-use marijuana program won’t start until more local approvals in place (Marijuana Business Daily)

// Maryland Governor Hogan Vetoes Bill Automatically Expunging Cannabis Convictions (Outlaw Report)


These headlines are brought to you by MJToday Media, publishers of this podcast as well as our weekly show Marijuana Today and the most-excellent Green Rush Podcast. And check out our new show Weed Wonks!


// Trulieve’s dominance in Florida increases again as many firms come to a standstill (Marijuana Business Daily)

// Epidiolex Growth Fuels GW Pharma Revenue Above Expectations to $120.6 Million (New Cannabis Ventures)

// Tilray Q1 Cannabis Revenue Grows 9% Sequentially to $30.8 Million (New Cannabis Ventures)

// Cronos Group Underwhelms Again with Just $8.4 Million Revenue and a $45.1 Million Operating Loss in Q1 (New Cannabis Ventures)

// Cannabis MSO Jushi cancels California acquisition, moves forward in Illinois (Marijuana Business Daily)

// Mass. cannabis executives ‘look forward to safely reopening’ after meeting with governor’s advisory board (Mass Live)

// Top Vermont Lawmaker Says Legal Marijuana Sales Bill Will Be Taken Up After Coronavirus Response (Marijuana Moment)


Check out our other projects:Marijuana Today— Our flagship title, a weekly podcast examining the world of marijuana business and activism with some of the smartest people in the industry and movement. • Marijuana Media Connect— A service that connects industry insiders in the legal marijuana industry with journalists, bloggers, and writers in need of expert sources for their stories.

Love these headlines? Love our podcast? Support our work with a financial contribution and become a patron.

Photo: Paul Noble Photography/Flickr

With Brexit Done, Why Won’t Boris Johnson Fix British Medical Cannabis?

Last summer, Boris Johnson, the rumpled former tabloid journalist and ex-mayor of London now serving as the press-hating prime minister of the United Kingdom, surrounded himself with weedheads.

With the hire of Blair Gibbs, a longtime cannabis-policy reform advocate and legalization supporter to a senior position at No. 10 Downing Street, it seemed Johnson was preparing for a post-Brexit Britain where medical cannabis was at last available to all Britons — and, within as little as five years, commercial recreational cannabis would follow.

But with Johnson’s adversaries in Jeremy Corbyn and Labour vanquished, and Britain finally exiting the European Union, where are we? In just the same place we were before, if not worse: cannabis illegal, sick children forced to break the law or pursue expensive and potentially harmful pharmaceutical cures, and nobody happy about any of it.

Except, maybe, for Johnson, who — despite supporting medical cannabis back in 2008, when he didn’t have any power — now doesn’t have to make any difficult decisions. Meanwhile, families of sick people are selling their family homes to pay for medicine.

With an election in the balance, Johnson promised in October to discuss medical cannabis access for epileptic children personally with a member of Parliament. As the Daily Record reported, Johnson broke that promise in January, dispatching instead an apparatchik to meet with elected officials.

Currently, medical cannabis is “legal” in Britain, but can’t be dispensed through the National Health Service except in extremely limited circumstances, meaning access is only for the rich or the lawbreakers. It can cost up to £3,500 pounds a month for a cannabis prescription through a private doctor, the BBC reported.

Since Nov. 1, 2018, when U.K. law “legalized” medical cannabis, only 18 patients have managed to get a prescription through NHS, as iNews reported. (Keep in mind that “saving” the U.K.’s vaunted single-payer healthcare system was part of how Brexit was sold to the massesbefore leading Brexiteers then started calling for U.S.-style privatization.)

Even when patients do obtain a prescription, treatment options are limited. Only two “cannabis-based” medicines have been approved for use in the United KingdomEpidiolex and Sativex, both developed by Britain-based GW Pharmaceuticals. One is prescribed for epilepsy, and the other is to treat multiple sclerosis — meaning anyone else, with chronic pain, or wasting syndrome from cancer, or insomnia, or autism, is screwed, even though companies like Canada-based Tilray have been advertising cannabis-oil imports since last summer.

A massive clinical trial project, meant to supply as many as 20,000 U.K. citizens with medical-grade cannabis products by 2021, is in the beginning stages, but in the meantime, policy in the U.K. is well behind that in other European countries like Italy and Germany — and well behind most U.S. states.

During an appearance on the BBC, Matt Hancock, Johnson’s secretary of health, blamed delays on drug companies, insisting that “it comes down to the drug companies to make them in the right way. They need to come to the table on this.” Except that’s a half-truth: NHS could subsidize drug costs, but is choosing not to. The NHS and related health officials could allow patients to access whole-plant medicine, if the Home Office allowed for citizens to grow cannabis at home — but none of that is happening.

And here’s Johnson. While a privileged teen at Eton, the U.K.’s posh prep school, Johnson is known to have had a “jolly nice” time smoking spliffs — he’s admitted as such.

Other world leaders oversee far more draconian drug policies. It’s not a list you want to be on: Vladimir Putin’s Russia, Rodrigo Duterte’s Philippines, Xi Jinping’s China. The difference is that none of them have called for reform or promised to do something about it, before changing their minds.

Now, as prime minister, Johnson is deporting longtime U.K. residents for minor cannabis offenses, and conveniently forgetting whatever rationale it was that led him to understand legal weed was a good idea back in 2008. In the meantime, in the post-industrial cities in Britain’s version of the U.S. Rust Belt, a drug-overdose crisis is brewing.

Does this sound familiar? It should! More and more, Johnson’s U.K. is resembling Donald Trump’s America, with one very large difference — without the (blue) states where cannabis is legal.

TELL US, do you have hope for medical cannabis in the U.K.?

The post With Brexit Done, Why Won’t Boris Johnson Fix British Medical Cannabis? appeared first on Cannabis Now.

U.K. Regulator FSA And Leading Trade Group CTA Lock Horns in CBD Spat

The Cannabis Trades Association and U.K. regulator the Food Standards Agency have crossed swords in a heated exchange over the legal status of CBD products.

In a response to questions posed by CBD Testers the FSA strongly countered claims made in a press release by the CTA. But, the CTA has hit back strongly – and CBD Testers has agreed to publish its feisty responses to the FSA’s answers.

This public row follows a CTA
press release summarising events at a meeting between the two parties on
European Novel Food authorisation, in November, last year.

The CTA’s press release can be found here: https://britishcannabis.org/cannabis-trades-association-gains-clarity-from-fsa-on-novel-status-of-cbd-products/

The FSA told CBD Testers it finds this summary a ‘misrepresentation’, ‘disappointing’ and ‘inaccurate’. However, the CTA has hit back at
the FSA with a series of counter-claims – detailed below.

As a result of last January’s European Commission Novel Food directive the European CBD market continues to exist in a haunting regulatory limbo. While the exchanges between the FSA and the CTA will do little to move the issue forward, they are an indication temperatures are rising on all sides.

Click here or use the sign up form below to subscribe to the CBD Business Weekly Newsletter.

A Brief Novel Food Summary

Over the last few years the rapidly-growing British CBD industry has developed a self-regulatory framework which, in the main, has been led by the CTA.

The CTA is by far the largest world-wide CBD trade organisation with around 1,000 member businesses in around 30 countries. However, a regulatory hand grenade was lobbed at the European CBD industry when the European Commission (E.C.) designated CBD a Novel Food, in January 2019.

New – or Novel – food products
have to undergo pre-market safety tests and secure approval from the EC before
they can be sold; a process which can take up to five years and cost up to
£500,000.

One massive issue for the CBD industry, here, is that once a submission has been made then a product must be removed from sale until approval is secured – effectively, a terminal event for most.

The Novel Food Catalogue has no legal weight but sets an enforcement benchmark for authorities in the 29 member states. In practice there has been little
enforcement in both the U.K, and the rest of Europe, and the CTA and other
European trade groups are fighting back.

They argue that CBD has been around in a plant extract form for hundreds of years and have provided evidence to that effect. And, it is pursuing an Article 4 submission with the EC which it hopes will secure recognition of this historical data and determine that CBD plant extracts  – but not isolates – are not new, or Novel.

EU Novel Food and The Legal Status of CBD Oil

Our questions to the FSA, its responses and the CTA’s comebacks:

Key:

  • CBD Testers
  • FSA
  • CTA

1. Has the FSA acknowledged the
legitimacy of the Article 4 challenge on Novel Food and agreed to allow CTA
members to continue to make and sell CBD products, unfettered by enforcement
action, while this progresses?

FSA: To date the FSA has not
received an Article 4 submission from the CTA, although these may be made to
any relevant Member State within the EU. An article 4 submission is something
that any business or relevant party may do where they are not certain if a food
is novel or not and should always be submitted before placing any foods on the
market.

As such the submission of an
Article 4 does not in any way remove responsibility to comply with novel foods
legislation, and no agreement has been made with the CTA (or any other
organisation/business) in relation to enforcement actions.

CBD extracts have been confirmed as novel foods, and any potential submission
of an Article 4 request does not alter this position, nor enforcement options
available.

CTA: The CTA has never stated
that the FSA agreed to allow CTA members to unconditionally continue to make
and sell CBD products, only that it agreed that following an article 4 
determination that they are not novel they would be completely isolated and
protected from enforcement.

They (FSA) agreed that following an article 4  determination that they are not novel they would becompletely isolated and protected from enforcement, the CTA is NOT making a submission in the UK and as such considers the UK FSA to be the least important of the players in the moment given the requirements of Article 50.

2. Is it right to say
there will be no ‘grace period’ for firms making Novel Food application, so in
effect they will not be able to make and sell CBD products for sale in the UK
while these applications are processed and considered by the EC?

FSA: CBD extracts were confirmed
as novel foods in January 2019.

CTA: Incorrect in Jan 2019 the
catalogue that is not legally binding and only serves as orientation, was
changed for the third time. This forms no confirmation of if CBD extracts are
novel or not. It’s merely an opinion that is in no way a legal determination.
Our QC has repeatedly stated that “ The approach
to the Novel Foods decision is massively inconsistent throughout the EU. In the
Czech Republic no one cares: Cannabis is entrenched in the food chain.
   In Germany the approach is strict but their Courts have
decided that the Commission’s Novel Food Catalogue constitutes merely an
indication that may be rebutted.  This is really a political issue, with
vested interests in the background. 
Is the FSA bluffing? In my view, the critical factor on enforcement
will be political, not legal, and the budget for enforcement will be also be a
vital factor.

FSA: As no relevant products have
so far gained authorisation, all CBD extracts being sold as food or food
supplements are doing so in contravention of the novel foods legislation.

CTA: This statement is false,
the novel status of CBD extracts has never been tested in law and extracts
would only be in contravention of the novel foods legislation if a legally
binding determination was made.

FSA: This position is the same,
whether or not any application for authorisation has been made. All novel foods
should gain the appropriate authorisation before being sold or marketed, and
this means all CBD extracts are subject to potential enforcement action
irrespective of if they have made an application or not.

CTA: This also means all CBD
extracts (including isolates) could be protected from enforcement.

FSA: An article 4 request will not
alter any enforcement position and offers no further protection against
enforcement.

CTA: Yet an Article 4
determination would offer protection against enforcement when the determination
is made that CBD extracts are not novel.

CBD Warnings From FDA Spook Major Consumer Brands

3.
Has the FSA concluded ‘CBD does not produce adverse effects and consequently
there will be on enforcement action’.

FSA: We are continuing to monitor
food safety aspects of CBD. The information available on CBD does not suggest
any significant safety concerns related to CBD,

CTA: This is very important,
why would any enforcement action take place, when there is no public safety
concern. Enforcement action would be a waste of taxpayers money, providing no
protection to public health, which would result in real issues of public health
not being addressed and the action placing the public in danger

FSA: But as part of the novel
foods authorisation process they do need to be evaluated for safety. If we find
evidence to say that CBD extracts in general, or specific products containing
CBD, risk harm to the public, they will be removed from sale.

4. And
finally is it waiting for a further submission from the CTA. As the statement
concludes: The CTA…(will be) submitting data around
the safety of CBD to be assessed at the next toxicology meeting in a few weeks’
time. Based on data that calls into question the reliability of their
supportive evidence, this could result in there being no safety concerns around
cannabis extracts and all enforcement action being cancelled moving forwards.

FSA: The CTA has told us that they intend to send us data on the safety of CBD, but so far no information has been received. We will review any information we’re sent

Importance of Stocking GMP Products in Your Shop

5. Ps.

FSA: For clarification, CTA shared
a draft of this news story with us in December.

CTA: This is incorrect we
shared it with them in November and they failed to respond until the week
before Christmas

FSA: We made it clear to
them via email before publication that their interpretation of our discussion
in November 2019 was incorrect.

CTA: This is completely false,
they only informed the CTA that they would not endorse and support the CTA
statement, at no point in the response did they make any claims that our
statement was incorrect. We do not expect any regulatory department to endorse
a statement that is made by any trade body. The FSA to this date, has not
claimed any of our statements are not factually correct. It would be impossible
for them to do so given there were 7 people in the meeting including a legal
representative that witnessed the responses the FSA made.

FSA: We addressed each of their
points and explained clearly how they had misinterpreted what was said at the
meeting. 

CTA: This is a false statement,
they did not address each of the points or did they say we had misinterpreted
what was said at the meeting. Just provided some generic information which
they thought we may find helpful.

FSA: We have written to the CTA
expressing our disappointment at their conduct and urged them to correct the
article to avoid misleading their members and disadvantaging them in working
towards compliance for their products. 

CTA: We have responded to the FSA and are in discussions with our legal team with regards the false, misleading and damaging claims now being made by the FSA with regards the CTA.  We are working closely with our assembled legal team and as such we are writing to the FSA separately to ensure that they cannot write letters to us that significantly change their position given that there was legal representation on behalf of the CTA in the room at the time.  We have refused to amend or remove our press release believing it to be a complete and correct response to the meeting and subsequent conversations we had at the time.

Importance of Stocking GMP Products in Your Shop

FSA: CBD is ‘Safe’

This spat will once more provoke
uncertainty amongst Europe’s booming CBD industry but there are some rays of
hope in the FSA’s answer to the questions posed by CBD Testers.

As for the first time, the FSA has
slid towards the widespread industry view over the safety of CBD products.

In its response to CBD Testers,
the FSA says: “We are continuing to monitor food safety aspects of CBD. The
information available on CBD does not suggest any significant safety concerns
related to CBD…”

While the FSA say it will look to
enforce the Novel Food regulations this newly-stated position on the safety of
CBD is unlikely to lead to any concerted enforcement action in the U.K.

FSA’s Current Position

For many months the FSA has
maintained the following public-facing position on Novel Foods, and it has
re-stated this as its current position to CBD Testers:

“CBD extracts are considered
novel foods under food law and we expect companies to comply with the novel
foods process, which includes submitting safety information about their
products.

“The FSA is considering the best way to ensure CBD food-related products currently on the market move towards compliance. We will be providing an update on this process and our position when we have completed those considerations.”

For more articles like this one, subscribe to the CBD Business Weekly Newsletter.

An Update On British CBD and the Novel Food Regulations in EU

The post U.K. Regulator FSA And Leading Trade Group CTA Lock Horns in CBD Spat appeared first on CBD Testers.

Tuesday, December 3, 2019 Headlines | Marijuana Today Daily News

Marijuana Today Daily Headlines
Tuesday, December 3, 2019 | Curated by host Shea Gunther

// Hundreds wait in line for first day of legalized recreational marijuana sales (Detroit Free Press)

// Federal Agency Adopts Policy Letting People With Drug Convictions Work At Credit Unions (Marijuana Moment)

// Charges stand in case of shipment from Vermont hemp farm seized by NYPD (Burlington Free Press)


These headlines are brought to you by Green Worx Consults, a company specializing in project management, workflow mapping and design, and Lean & 6 Sigma process. If you could use help making your business better at business, get in touch with Green Worx Consults.


// Top Drug Treatment Providers Push UK Government To Consider Decriminalization (Marijuana Moment)

// Arkansas may revoke retailers’ inactive medical pot licenses (CT Post (AP))

// Shoppers Drug Mart medical cannabis portal goes national (Winnipeg Free Press)

// SOL Global Reports $51 Million Loss (Green Market Report)

// Could Life Insurance Go Up in Smoke for Some Vapers? (New York Times (Reuters))

// Is the vape scare affecting the cannabis market? (Leafly)

// Canadian islanders angry over US mail searches (BBC News)


Check out our other projects:
Marijuana Today— Our flagship title, a weekly podcast examining the world of marijuana business and activism with some of the smartest people in the industry and movement.
Marijuana Media Connect— A service that connects industry insiders in the legal marijuana industry with journalists, bloggers, and writers in need of expert sources for their stories.

Love these headlines? Love our podcast? Support our work with a financial contribution and become a patron.

Photo: Stock Catalog/Flickr